Research, PHARMA TECH

AI Powered Business Intelligence for Life Science Leaders: Save Time, Drive Adoption and Scale Faster

February 20, 2023

AI Powered Business
Once the industry has normalized after a turbulent 2020,
life sciences leaders can still count on continued change.
The future will be challenging at best without the support
of next-gen BI as life sciences navigate their businesses
through new or growing competition, economic recovery,
regulatory and political pressures, barriers to market access,
and an increased demand for personalized medicine.

Spotlight

Oliver Wyman

Oliver Wyman is a global leader in management consulting. With offices in 50+ cities across nearly 30 countries, Oliver Wyman combines deep industry knowledge with specialized expertise in strategy, operations, risk management, and organization transformation. The firm has more than 5,000 professionals around the world who help clients optimize their business, improve their operations and risk profile, and accelerate their organizational performance to seize the most attractive opportunities. Oliver Wyman is a wholly owned subsidiary of Marsh & McLennan Companies.

OTHER WHITEPAPERS
news image

Getting serious about serialization: A comprehensive look at thelegislation shaping U.S. pharmaceutical supply chains

whitePaper | October 7, 2022

The Drug Supply Chain Security Act is one component of the DQSA. This particular act requires the FDA to implement a national track-and-trace system by which manufacturers must affix product identifiers (barcodes) to each package of product that is introduced into the supply chain.

Read More
news image

NEXTGEN PHARMA TAKES ‘SMART’ STRIDES WITH INTERNET OF THINGS

whitePaper | December 20, 2022

Digitization of processes and data across the value chain along with the emergence of Internet of Things (IoT) has transformed the Pharma industry.

Read More
news image

The Use of Real-World Data for Personalized Medicine

whitePaper | June 5, 2022

Although our growing scientific understanding and improvements made in medical technology lead to significant advances in human health and wellbeing, many therapy strategies remain insufficient,

Read More
news image

Investing in Next-Generation Tokenization and Real-World Data to Unlock a More Precise and Complete Patient Journey

whitePaper | November 18, 2022

To realize the full potential of RWD, we must put the patient at the center and truly understand each patient’s unique circumstances over time. It’s certainly a tall order when the data we need is scattered across siloed systems and guarded by applicable and necessary patient privacy regulations.

Read More
news image

Redefining the Role of Health Systems as a Specialty Pharmacy Solution for Drug Manufacturers

whitePaper | January 10, 2023

The ideal care model for complex patients is a model in which the entire health care team is made up of experts in the specific disease state being treated. Integrated health care systems and major academic medical centers provide this level of expertise and coordination.

Read More
news image

Optimizing the Path from Pre-Clinical to Clinical Development

whitePaper | December 22, 2022

According to research, post-pandemic R&D growth is healthy in the pharma industry with the number of drugs in the R&D pipeline now exceeding 20,000 in 2022—which represents an expansion rate of 8.22% from 2021 (1).

Read More

Spotlight

Oliver Wyman

Oliver Wyman is a global leader in management consulting. With offices in 50+ cities across nearly 30 countries, Oliver Wyman combines deep industry knowledge with specialized expertise in strategy, operations, risk management, and organization transformation. The firm has more than 5,000 professionals around the world who help clients optimize their business, improve their operations and risk profile, and accelerate their organizational performance to seize the most attractive opportunities. Oliver Wyman is a wholly owned subsidiary of Marsh & McLennan Companies.

Events